Dividends & Buybacks ·
Cellyan Biotechnology Co., Ltd. held an extraordinary general meeting on September 21, 2026, where shareholders…
HKPDCellyan Biotechnology Co., Ltd
Cellyan Biotechnology Co., Ltd. held an extraordinary general meeting on September 21, 2026, where shareholders approved a one-for-twenty share consolidation of its Class A and Class B ordinary shares. The transaction increases the par value from US$0.001 to US$0.02 per share and reduces authorized shares from 1 billion to 50 million. Fractional shares will be converted into whole shares, with any remainder paid in cash or adjusted as determined by Nasdaq. This corporate action aims to meet Nasdaq's minimum bid price requirements. The company operates in the biotechnology industry.